What is Leerink Partnrs’ Forecast for VIR FY2026 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Investment analysts at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for shares of Vir Biotechnology in a research report issued on Wednesday, November 20th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will earn ($4.05) per share for the year, down from their previous forecast of ($3.55). The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.30) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s FY2027 earnings at ($2.80) EPS.

Other equities analysts have also issued research reports about the company. Barclays cut their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Wednesday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Price Performance

NASDAQ VIR opened at $7.12 on Friday. Vir Biotechnology has a 1 year low of $6.56 and a 1 year high of $13.09. The company has a market capitalization of $980.57 million, a PE ratio of -1.82 and a beta of 0.46. The company has a fifty day moving average of $7.91 and a 200 day moving average of $8.86.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business’s revenue was down 9.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.22) EPS.

Institutional Trading of Vir Biotechnology

Several hedge funds have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Vir Biotechnology by 1.3% during the 3rd quarter. Barclays PLC now owns 550,186 shares of the company’s stock worth $4,121,000 after acquiring an additional 7,287 shares in the last quarter. State Street Corp grew its position in shares of Vir Biotechnology by 10.4% in the 3rd quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after buying an additional 530,645 shares during the last quarter. Quarry LP lifted its position in Vir Biotechnology by 901.8% in the third quarter. Quarry LP now owns 17,000 shares of the company’s stock valued at $127,000 after acquiring an additional 15,303 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Vir Biotechnology by 10.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 350,265 shares of the company’s stock valued at $2,623,000 after acquiring an additional 33,473 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Vir Biotechnology during the third quarter worth about $217,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the sale, the director now owns 11,616 shares of the company’s stock, valued at $90,604.80. The trade was a 51.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders sold 15,940 shares of company stock worth $127,410. 15.60% of the stock is currently owned by company insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).